Endocrinology

>

Latest News

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency | © Contemporary Pediatrics
FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

July 8th 2025

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia | Image Credit: © lexiconimages - © lexiconimages - stock.adobe.com.
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia

June 9th 2025

FDA accepts navepegritide application to treat children with achondroplasia | Image credit: Contemporary Pediatrics
FDA accepts navepegritide application to treat children with achondroplasia

June 2nd 2025

FDA approves hydrocortisone oral solution for children 5 years, older with adrenocortical insufficiency | Image credit: Contemporary Pediatrics
FDA approves hydrocortisone oral solution for children 5 years, older with adrenocortical insufficiency

May 29th 2025

Phase 3 data show effectiveness of somapacitan in children with growth disorders | Image Credit: © Saiful52- © Saiful52  - stock.adobe.com.
Phase 3 data show effectiveness of somapacitan in children with growth disorders

May 15th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.